基于乳腺癌免疫逃逸的的作用机制与细胞遗传学分析的 医学研究与卫生经济学讨论

秦 　祎¹, 廖 艺涵², 刘 振雨², 夏 　媛³
1、赤峰市肿瘤医院（赤峰学院第二附属医院）肿瘤内科
2、白俄罗斯国立大学萨哈罗夫研究所
3、湖南医药学院医学院

摘要

乳腺癌是发生在乳腺癌部位的肿瘤，往往都是恶性的，肿瘤的发生机制中，最重要的就是肿瘤的免疫逃逸，
肿瘤发生免疫逃逸后，人类的免疫系统往往无法对其进行监视，这就会导致肿瘤的扩散，细胞遗传学是研究肿瘤细
胞DNA与细胞增殖的基础，我们尝试对肿瘤细胞的DNA突变进行分析并得出结论，笔者结合卫生经济学进行讨论。

关键词

乳腺癌；免疫学；细胞遗传学；卫生经济学

参考

[1]Abdulkareem, Imran Haruna. “Aetio-pathogenesis of

breast cancer.” Nigerian medical journal: journal of the Nigeria

Medical Association 54.6 (2013): 371.

[2]Shah, Nirav R., and Hexin Chen. “MicroRNAs in

pathogenesis of breast cancer: Implications in diagnosis and

treatment.” World journal of clinical oncology 5.2 (2014): 48.

[3]Rahmani, Farzad, et al. “Role of regulatory miRNAs of

the PI3K/AKT signaling pathway in the pathogenesis of breast

cancer.” Gene 737 (2020): 144459.

[4]Bahreyni, Amirhossein, et al. “Role of adenosine

signaling in the pathogenesis of breast cancer.” Journal of

Cellular Physiology 233.3 (2018): 1836-1843.

[5]Sovak, Mika A., et al. “Aberrant nuclear factor_xfffe_kappaB/Rel expression and the pathogenesis of breast cancer.”

The Journal of clinical investigation 100.12 (1997): 2952-

2960.

[6]Mukhopadhyay, P., Chakraborty, S., Ponnusamy, M.

P., Lakshmanan, I., Jain, M., & Batra, S. K. (2011). Mucins in

the pathogenesis of breast cancer: implications in diagnosis,

prognosis and therapy. Biochimica et Biophysica Acta (BBA)-

Reviews on Cancer, 1815(2), 224-240.

[7]King, Jeronay, Hina Mir, and Shailesh Singh.

“Association of cytokines and chemokines in pathogenesis

of breast cancer.” Progress in Molecular Biology and

Translational Science 151 (2017): 113-136.

[8]Niu, Tong, Weiwei Zhang, and Wei Xiao. “MicroRNA

regulation of cancer stem cells in the pathogenesis of breast

cancer.” Cancer Cell International 21.1 (2021): 1-14.

[9]Ghafouri-Fard, Soudeh, et al. “An update on the

role of long non-coding RNAs in the pathogenesis of breast

cancer.” Pathology-Research and Practice 219 (2021):

153373.

[10]Khoshakhlagh, M., Soleimani, A., Binabaj, M. M.,

Avan, A., Ferns, G. A., Khazaei, M., & Hassanian, S. M. (2019).

Therapeutic potential of pharmacological TGF-β signaling

pathway inhibitors in the pathogenesis of breast cancer.

Biochemical Pharmacology, 164, 17-22.

[11]Daemen, Anneleen, et al. “Erratum to: Modeling

precision treatment of breast cancer.” Genome biology 16.1

(2015): 1-3.

[12]Zhang, Y., Zhang, D., Meng, Q., Liu, Z., Xie, H., Liu,

L., ... & Chen, X. (2021). Precision treatment exploration of

breast cancer based on heterogeneity analysis of lncRNAs at

the single-cell level. BMC cancer, 21(1), 1-15.

[13]Arnedos, M., Vicier, C., Loi, S., Lefebvre, C.,

Michiels, S., Bonnefoi, H., & Andre, F. (2015). Precision

medicine for metastatic breast cancer— limitations and

solutions. Nature reviews Clinical oncology, 12(12), 693-704.